<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="lary32163" xml:lang="en" article-type="other" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Laryngoscope</journal-id><journal-id journal-id-type="iso-abbrev">Laryngoscope</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">LARY</journal-id><journal-title-group><journal-title>The Laryngoscope</journal-title></journal-title-group><issn pub-type="ppub">0023-852X</issn><issn pub-type="epub">1531-4995</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475553</article-id><article-id pub-id-type="pmcid-ver">PMC12475553.1</article-id><article-id pub-id-type="pmcaid">12475553</article-id><article-id pub-id-type="pmcaiid">12475553</article-id><article-id pub-id-type="pmid">40227970</article-id><article-id pub-id-type="doi">10.1002/lary.32163</article-id><article-id pub-id-type="publisher-id">LARY32163</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Triological Society Best Practice</subject></subj-group><subj-group subj-group-type="heading"><subject>Triological Society Best Practice</subject></subj-group></article-categories><title-group><article-title>Operating Room or In&#8208;Office Injection for Retrograde Cricopharyngeal Dysfunction Botulinum Toxin Injection</article-title></title-group><contrib-group><contrib id="lary32163-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>AlRashed AlHumaid</surname><given-names initials="S">Salwa</given-names></name><xref rid="lary32163-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>salwa.r.h@gmail.com</email></address></contrib><contrib id="lary32163-cr-0002" contrib-type="author"><name name-style="western"><surname>Silver</surname><given-names initials="JA">Jennifer A.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7896-8367</contrib-id><xref rid="lary32163-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="lary32163-cr-0003" contrib-type="author"><name name-style="western"><surname>Kost</surname><given-names initials="KM">Karen M.</given-names></name><xref rid="lary32163-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="lary32163-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Otolaryngology, Montreal General Hospital, McGill University</institution>
<city>Montreal</city>
<country country="CA">Canada</country>
</aff><aff id="lary32163-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Otolaryngology&#8208;Head and Neck Surgery</named-content>
<institution>McGill University</institution>
<city>Montreal</city>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Salwa AlRashed AlHumaid (<email>salwa.r.h@gmail.com</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2025</year></pub-date><volume>135</volume><issue seq="30">10</issue><issue-id pub-id-type="pmc-issue-id">497679</issue-id><issue-id pub-id-type="doi">10.1002/lary.v135.10</issue-id><fpage>3467</fpage><lpage>3469</lpage><history><date date-type="rev-recd"><day>19</day><month>3</month><year>2025</year></date><date date-type="received"><day>10</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 00:25:15.170"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">The Laryngoscope</italic> published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="LARY-135-3467.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:LARY-135-3467.pdf"/><abstract><title>ABSTRACT</title><sec id="lary32163-sec-0001"><title>Background</title><p>Retrograde Cricopharyngeal Dysfunction (RCPD), also known as &#8220;No Burp Syndrome,&#8221; is a rare condition characterized by the inability to burp due to cricopharyngeus muscle dysfunction. Patients experience bloating, chest and abdominal discomfort, gurgling sounds, and excessive flatulence, which significantly impact quality of life.</p></sec><sec id="lary32163-sec-3502"><title>Objective</title><p>To compare the clinical outcomes and side effect profiles of botulinum toxin injection for RCPD when performed in&#8208;office versus in the operating room.</p></sec><sec id="lary32163-sec-0003"><title>Methods</title><p>A clinical review of patients with RCPD was conducted, focusing on diagnosis based on history and physical examination. Botulinum toxin was administered to the cricopharyngeus muscle either in&#8208;office or in the operating room. Success rates, complications, and patient tolerance were analyzed and compared across both procedural settings.</p></sec><sec id="lary32163-sec-0004"><title>Results</title><p>Botulinum toxin injection proved effective in both settings, with similar success rates in restoring the ability to burp and relieving associated symptoms. In&#8208;office procedures offered advantages in convenience and recovery time, while operating room procedures allowed for greater procedural control under general anesthesia. Side effect profiles differed slightly, with transient throat discomfort more commonly reported in in&#8208;office cases.</p></sec><sec id="lary32163-sec-0005"><title>Conclusion</title><p>Both in&#8208;office and operating room botulinum toxin injections are effective treatment options for RCPD. The choice of setting should be guided by patient preference, comorbidities, and resource availability, as each approach offers distinct advantages and risk considerations.</p></sec><sec id="lary32163-sec-7002"><title>Level of Evidence</title><p>The retrospective case series by Bastian et&#160;al. Wajsberg et&#160;al. Hoesli et&#160;al. and Doruk and Pitman are level III evidence. The prospective cohort study of Doruk et&#160;al. is level II evidence.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="lary32163-kwd-0001">clinical practice guidelines laryngology</kwd><kwd id="lary32163-kwd-0002">laryngology</kwd><kwd id="lary32163-kwd-0003">quality of life</kwd><kwd id="lary32163-kwd-0004">upper esophageal sphincter laryngology</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><page-count count="3"/><word-count count="1700"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>October 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:27.09.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="lary32163-cit-1001"><string-name name-style="western"><given-names>S.</given-names><surname>AlRashed AlHumaid</surname></string-name>, <string-name name-style="western"><given-names>J. A.</given-names><surname>Silver</surname></string-name>, and <string-name name-style="western"><given-names>K. M.</given-names><surname>Kost</surname></string-name>, &#8220;<article-title>Operating Room or In&#8208;Office Injection for Retrograde Cricopharyngeal Dysfunction Botulinum Toxin Injection</article-title>,&#8221; <source>The Laryngoscope</source><volume>135</volume>, no. <issue>10</issue> (<year>2025</year>): <fpage>3467</fpage>&#8211;<lpage>3469</lpage>, <pub-id pub-id-type="doi">10.1002/lary.32163</pub-id>.<pub-id pub-id-type="pmcid">PMC12475553</pub-id><pub-id pub-id-type="pmid">40227970</pub-id></mixed-citation>
</p><fn-group id="lary32163-ntgp-0001"><fn fn-type="funding" id="lary32163-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn></fn-group></notes></front><body id="lary32163-body-0001"><sec sec-type="background" id="lary32163-sec-4003"><label>1</label><title>Background</title><p>Retrograde cricopharyngeal dysfunction (RCPD), commonly known as &#8220;No Burp Syndrome,&#8221; is characterized by an inability to burp [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>]. Symptoms include bloating, gurgling sounds, chest and abdominal discomfort, and excessive flatulence, all contributing to a reduced quality of life (QOL) [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>].</p><p>The cricopharyngeus muscle relaxes during swallowing and burping. to allow for the release of air. In patients with RCPD, relaxation during burping does not occur effectively, leading to the aforementioned symptoms [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>]. Although the etiology of RCPD remains unclear, one hypothesis is that abnormalities in the nerve signals controlling the upper esophageal sphincter (UES) result in inadequate muscle relaxation. Anxiety and stress may exacerbate symptoms by influencing muscle tension [<xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>]. Literature suggests that RCPD has a higher prevalence amongst younger, female patients and in individuals with underlying anxiety disorders or other neuromuscular conditions [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>].</p><p>RCPD is a clinical diagnosis made following a comprehensive history and physical examination. Botulinum toxin injection to chemically denervate the CP muscle has been proposed as both diagnostic and therapeutic for this disorder [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>]. Botulinum toxin injection can be performed in the operating room (OR) or in&#8208;office, with specific risks and benefits to each, driving physician and patient preference.</p></sec><sec id="lary32163-sec-4504"><label>2</label><title>Literature Review</title><p>The resultant effect of the injection of botulinum toxin into the cricopharyngeus muscle confirms the diagnosis of RCPD and is also the mainstay of treatment [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>]. The injection facilitates relaxation of the CP, thereby enabling burping, alleviating symptoms, and improving QOL simultaneously [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>]. The standard practice amongst most otolaryngologists treating RCPD is injection in the OR [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>, <xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>, <xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>, <xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>, <xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. However, a number of otolaryngologists are now opting to inject botulinum toxin endoscopically in&#8208;office [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>, <xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>, <xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>, <xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>, <xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. Patients experience improvement in symptoms within several days and the majority require just one injection to create lasting results [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>, <xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>, <xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>, <xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>, <xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. While Botulinum toxin injection into the CP muscle is generally considered safe, potential side effects are often related to the injection technique (i.e., risks of general anesthesia, surgical equipment) or diffusion of the Botulinum toxin into laryngeal muscles (posterior cricoarytenoid muscle) and pharyngeal muscles (inferior constrictor muscles), causing shortness of breath or &#8216;noisy breathing&#8217; and dysphagia. Follow&#8208;up is essential to establish efficacy, assess for potential complications, and determine if repeat injections are needed [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>].</p><sec id="lary32163-sec-5405"><label>2.1</label><title>Botulinum Toxin Injection Techniques</title><p>In the OR under general anesthesia, the bulge of the CP muscle is first exposed with the appropriate endoscope, then palpated, and injected with Botulinum toxin at multiple sites (central and lateral, deep and superficial) [<xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. Different dosages of Botulinum toxin have been described, ranging from 25&#8201;units to 100 units [<xref rid="lary32163-bib-0001" ref-type="bibr">1</xref>, <xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>, <xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>, <xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>, <xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>].</p><p>In&#8208;office Botulinum toxin injections may involve topicalization of the airway and are often performed under electromyography (EMG) guidance to more accurately localize the CP muscle. The percutaneous approach to the CP muscle is well known, and has been reported for the treatment of dysphagia due to CP dysfunction. The trans&#8208;cricothyroid membrane and lateral transcervical approaches are described in&#8208;office techniques to access the CP muscle for RCPD Botulinum toxin injections. The trans&#8208;cricothyroid membrane technique involved topicalization of the airway, then passing the injection needle via the membrane, through the airway lumen, the posterior cricoid plate, and posterior cricoarytenoid muscles to reach the CP muscle, which is injected after confirmation of location per EMG. The lateral transcervical approach does not require topicalization. In this method, the needle is inserted into the neck using the anatomic landmarks of the anterior border of the sternocleidomastoid muscle and the mid&#8208;level of the anterior cricoid ring, to inject into the CP muscle once the position is confirmed on EMG.</p></sec><sec id="lary32163-sec-4406"><label>2.2</label><title>Efficacy?</title><p>In a series of 200 RCPD patients treated in the OR, 99% were able to burp post&#8208;operatively. Six months later, approximately 80% of this cohort maintained the ability to burp, which is beyond the expected several month duration of action of botulinum toxin [<xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. Wajsberg et&#160;al. reported on 18 patients who underwent in&#8208;office trans cricothyroid injection of botulinum toxin for RCPD and 80% of these patients maintained their ability to burp at 6&#8201;months [<xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>].</p><p>Doruk et&#160;al.'s prospective study compared patients undergoing Botulinum toxinc injection in the OR and in&#8208;office [<xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>]. The study showed a decrease in symptom burden post injection in both cohorts (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.0001), with no statistically significant difference between the groups (<italic toggle="yes">p</italic>&#8201;=&#8201;0.4924) [<xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>].</p><p>However, in another study that defined success of injection as an 80% reduction of symptoms, the authors found that there was a statistically higher success rate in the OR cohort (<italic toggle="yes">n</italic>&#8201;=&#8201;41, success in 90.8%) compared to the in&#8208;office patients (<italic toggle="yes">n</italic>&#8201;=&#8201;37, success in 64.9%) (<italic toggle="yes">p</italic>&#8201;=&#8201;0.022) [<xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>]. Success rates may vary based on the definition of success (binary responses, symptom&#8208;based questionnaires, subjective or objective thresholds) and time of follow&#8208;up. In this study, in&#8208;office patients were injected with only 30&#8201;units of Botulinum toxin unilaterally to minimize complications, as compared with 80&#8201;units injected in the OR.</p></sec><sec id="lary32163-sec-0007"><label>2.3</label><title>Complications?</title><p>The reported complications following Botulinum toxin injection in the OR are minor and often secondary to anesthesia and laryngoscopy/esophagoscopy [<xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. The complications related to OR injection included laryngospasm during the intervention and subsequent post&#8208;obstructive pulmonary edema, dental injury, and pharyngeal wall injury [<xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. Given the ability to see, palpate, and inject the toxin into the CP muscle under direct vision in the OR, improper placement of the toxin, and its secondary effects, is less commonly described [<xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>].</p><p>In&#8208;office injection avoids the risks of general anesthesia and surgical injury but is associated with a greater risk of the Botulinum toxin injection itself [<xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>]. The proximity of the CP muscle to the posterior cricoarytenoid muscles and pharyngeal muscles is such that if diffusion of the toxin occurs, impairment of the posterior cricoarytenoid muscle function can lead to transient noisy breathing and shortness of breath and/or dysphagia, depending on the muscles impacted. In in&#8208;office trans&#8208;cricothyroid injections, 7/18 patients had breathing difficulties which were managed with breathing exercises [<xref rid="lary32163-bib-0004" ref-type="bibr">4</xref>].</p><p>Dysphagia rates were found to be different between the techniques. In the study by Doruk and Pitman, 46% of patients who underwent lateral approach in&#8208;office injections and 66% of those who underwent OR injections had dysphagia post injection ranging from experiencing &#8220;the feeling of food getting stuck&#8221; to adapting to a pureed diet. All patients in their study recovered with no residual dysphagia [<xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>].</p><p>In Doruk et&#160;al.'s prospective study, patients undergoing OR injections had more dysphagia post injection compared with those treated in&#8208;office (<italic toggle="yes">p</italic>&#8201;=&#8201;0.0379), possibly to be due to the higher doses of botulinum toxin used in OR [<xref rid="lary32163-bib-0002" ref-type="bibr">2</xref>]. Despite these higher rates of dysphagia generally reported, Hoesli et&#160;al. treated 200 patients in the OR with only 1/200 reporting dysphagia [<xref rid="lary32163-bib-0005" ref-type="bibr">5</xref>]. A hypothesis is that patients in this cohort were counseled to expect 1&#8211;2&#8201;weeks of altered swallowing and early dysphagia that was not recorded at the initial one&#8208;week follow&#8208;up had resolved by the second follow&#8208;up at 6&#8201;weeks. Two patients in the in&#8208;office cohort had post injection hoarseness, with one having unilateral vocal fold paralysis that did not limit his functionality [<xref rid="lary32163-bib-0003" ref-type="bibr">3</xref>].</p></sec></sec><sec id="lary32163-sec-0008"><label>3</label><title>Best Practice Statement</title><p>The current literature demonstrates that RCPD can be effectively treated in the majority of patients with Botulinum toxin injection into the CP muscle. Whether performed in the OR or in&#8208;office, both approaches have similar success rates but different side effect profiles. Surgeons comfortable with both techniques should involve their patients in the decision&#8208;making process by discussing the relative risks and benefits of each, allowing for a more personalized treatment approach.</p></sec><sec sec-type="COI-statement" id="lary32163-sec-0009"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec></body><back><ref-list content-type="cited-references" id="lary32163-bibl-0001"><title>References</title><ref id="lary32163-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="lary32163-cit-0001"><string-name name-style="western"><given-names>R. W.</given-names><surname>Bastian</surname></string-name> and <string-name name-style="western"><given-names>M. L.</given-names><surname>Smithson</surname></string-name>, &#8220;<article-title>Inability to Belch and Associated Symptoms due to Retrograde Cricopharyngeus Dysfunction: Diagnosis and Treatment</article-title>,&#8221; <source>OTO Open</source><volume>3</volume> (<year>2019</year>): <elocation-id>2473974x19834553</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2473974X19834553</pub-id><pub-id pub-id-type="pmcid">PMC6572913</pub-id><pub-id pub-id-type="pmid">31236539</pub-id></mixed-citation></ref><ref id="lary32163-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="lary32163-cit-0002"><string-name name-style="western"><given-names>C.</given-names><surname>Doruk</surname></string-name>, <string-name name-style="western"><given-names>E. L.</given-names><surname>Kennedy</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Tipton</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Abdel&#8208;Aty</surname></string-name>, and <string-name name-style="western"><given-names>M. J.</given-names><surname>Pitman</surname></string-name>, &#8220;<article-title>Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction: A Prospective Cohort Study</article-title>,&#8221; <source>Laryngoscope</source><volume>134</volume> (<year>2024</year>): <fpage>4614</fpage>&#8211;<lpage>4619</lpage>.<pub-id pub-id-type="pmid">38895836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.31591</pub-id></mixed-citation></ref><ref id="lary32163-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="lary32163-cit-0003"><string-name name-style="western"><given-names>C.</given-names><surname>Doruk</surname></string-name> and <string-name name-style="western"><given-names>M. J.</given-names><surname>Pitman</surname></string-name>, &#8220;<article-title>Lateral Transcervical In&#8208;Office Botulinum Toxin Injection for Retrograde Cricopharyngeal Dysfunction</article-title>,&#8221; <source>Laryngoscope</source><volume>134</volume> (<year>2024</year>): <fpage>283</fpage>&#8211;<lpage>286</lpage>.<pub-id pub-id-type="pmid">37421251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/lary.30871</pub-id></mixed-citation></ref><ref id="lary32163-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="lary32163-cit-0004"><string-name name-style="western"><given-names>B.</given-names><surname>Wajsberg</surname></string-name>, <string-name name-style="western"><given-names>R. C.</given-names><surname>Hoesli</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Wingo</surname></string-name>, and <string-name name-style="western"><given-names>R. W.</given-names><surname>Bastian</surname></string-name>, &#8220;<article-title>Efficacy and Safety of Electromyography&#8208;Guided Injection of Botulinum Toxin to Treat Retrograde Cricopharyngeus Dysfunction</article-title>,&#8221; <source>OTO Open</source><volume>5</volume> (<year>2021</year>): <elocation-id>2473974x21989587</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2473974X21989587</pub-id><pub-id pub-id-type="pmcid">PMC7863157</pub-id><pub-id pub-id-type="pmid">33598599</pub-id></mixed-citation></ref><ref id="lary32163-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="lary32163-cit-0005"><string-name name-style="western"><given-names>R. C.</given-names><surname>Hoesli</surname></string-name>, <string-name name-style="western"><given-names>M. L.</given-names><surname>Wingo</surname></string-name>, and <string-name name-style="western"><given-names>R. W.</given-names><surname>Bastian</surname></string-name>, &#8220;<article-title>The Long&#8208;Term Efficacy of Botulinum Toxin Injection to Treat Retrograde Cricopharyngeus Dysfunction</article-title>,&#8221; <source>OTO Open</source><volume>4</volume> (<year>2020</year>): <elocation-id>2473974x20938342</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2473974X20938342</pub-id><pub-id pub-id-type="pmcid">PMC7325547</pub-id><pub-id pub-id-type="pmid">32647778</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>